

DRUGS AND THE PHARMACEUTICAL SCIENCES

VOLUME 139

New Drug Approval Process

Fourth Edition
Accelerating Global Registrations

edited by
Richard A. Guarino, M.D.

atic-Pharma-
ko and Ste-

Biopharma-
nn Rüttinger
Edition, Re-
I H. Wachter
ised and Ex-

Rolland and

hn C. Bloom

aac Ghebre-
I Edition, Re-
ations, Fourth
Devices, and
iological Pro-
by Louis Rey

pment, edited
y
ig Global Reg-
cturing, edited

linical Pharm-
G. Sahajwala
stical Industry,

edited by Leon

ss, edited by Ira

arket, edited by

New Drug Approval Process

Fourth Edition
Accelerating Global Registrations

edited by
Richard A. Guarino, M.D.
Oxford Pharmaceutical Resources, Inc.
Totowa, New Jersey, U.S.A.



MARCEL DEKKER, INC.

NEW YORK • BASEL

The third edition was published as *New Drug Approval Process: Third Edition, The Global Challenge*.

Although great care has been taken to provide accurate and current information, neither the author(s) nor the publisher, nor anyone else associated with this publication, shall be liable for any loss, damage, or liability directly or indirectly caused or alleged to be caused by this book. The material contained herein is not intended to provide specific advice or recommendations for any specific situation.

Trademark notice: Product or corporate names may be trademarks or registered trademarks and are used only for identification and explanation without intent to infringe.

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress.

ISBN: 0-8247-5041-1

This book is printed on acid-free paper.

Headquarters

Marcel Dekker, Inc., 270 Madison Avenue, New York, NY 10016, U.S.A.
tel: 212-696-9000; fax: 212-685-4540

Distribution and Customer Service

Marcel Dekker, Inc., Cimarron Road, Monticello, New York 12701, U.S.A.
tel: 800-228-1160; fax: 845-796-1772

Eastern Hemisphere Distribution

Marcel Dekker AG, Hutgasse 4, Postfach 812, CH-4001 Basel, Switzerland
tel: 41-61-260-6300; fax: 41-61-260-6333

World Wide Web

<http://www.dekker.com>

The publisher offers discounts on this book when ordered in bulk quantities. For more information, write to Special Sales Professional Marketing at the headquarters address above.

Copyright © 2004 by Marcel Dekker, Inc. All Rights Reserved.

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

Current printing (last digit):

10 9 8 7 6 5 4 3 2 1

PRINTED IN THE UNITED STATES OF AMERICA

10

Clinical Research Protocols

Richard A. Guarino

Oxford Pharmaceutical Resources, Inc., Totowa, New Jersey, U.S.A.

I. INTRODUCTION

The practice of clinical research—to establish safety and efficacy for new drugs, devices, and biologicals—is considered the most important part of the new drug approval process by many individuals in the FDA, sponsor companies, and users of pharmaceutical products. Accomplishing this task requires careful strategic planning to meet research objectives, an available subject population that meets the criteria of trial requirements, and experienced well trained clinical investigators who can evaluate the trial subjects following the protocol design.

Clinical research protocols are key to assuring successful approvals of new products in the health care industry. The protocol becomes the Bible for each research program. It must be followed exactly, without deviations, and must be the reference for any discussions that arise during the course of the investigation. This chapter will give instructions on how to write a clinical protocol for all phases of clinical research. It will include all necessary FDA requirements for confirming safety and efficacy for products marketed for human use. The format for protocol development is recommended on the basis of its successful use in clinical research. The recommendations throughout this chapter may not always be applicable to all clinical programs.

The objective of most clinical trials is to record scientific data concerning the efficacy and safety of a treatment for a specific disease on which valid conclusions can be drawn. The degree of success in achieving this objective depends largely, but not entirely, on the quality of the basic trial

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.